EBSHIGH SIGNALFINANCIAL10-K

EBS experienced a substantial revenue decline alongside significant cost reductions and debt paydown, indicating major operational restructuring.

The meaningful revenue decrease coupled with proportionally larger SG&A expense reductions suggests aggressive cost-cutting measures in response to business headwinds. The company's ability to reduce debt by $110 million while maintaining higher current assets demonstrates solid liquidity management during this transition period.

Comparing 2026-02-27 vs 2025-03-04View on EDGAR →
FINANCIAL ANALYSIS

EBS saw substantial revenue decline from $1.0B to $742.9M, but responded with even more aggressive cost reduction, cutting SG&A expenses from $308M to $186M and reducing R&D spending by nearly 25%. Despite the revenue pressure, the company strengthened its balance sheet by paying down $110M in debt and increasing current assets to $662.5M, while reducing overall liabilities by over $100M, suggesting disciplined capital allocation during a challenging operating environment.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
-45.5%
$154.5M→$84.2M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Capital Expenditure
Cash Flow
-39.7%
$22.9M→$13.8M

Capex reduced 39.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

SG&A Expense
P&L
-39.6%
$308.0M→$186.1M

SG&A reduced 39.6% — improved cost efficiency or headcount reduction improving operating margins.

Revenue
P&L
-28.8%
$1.0B→$742.9M

Revenue softened 28.8% — monitor whether this is cyclical or structural.

R&D Expense
P&L
-24.8%
$70.7M→$53.2M

R&D spending cut 24.8% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
-18.6%
$162.4M→$132.2M

Current liabilities reduced — improved short-term financial position and working capital health.

Gross Profit
P&L
-17.7%
$385.8M→$317.6M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Total Debt
Balance Sheet
-15.8%
$700.0M→$589.7M

Debt reduced 15.8% — deleveraging strengthens balance sheet and reduces financial risk.

Total Liabilities
Balance Sheet
-12.2%
$906.9M→$796.0M

Liabilities reduced 12.2% — deleveraging improves balance sheet strength and financial flexibility.

Current Assets
Balance Sheet
+10.7%
$598.7M→$662.5M

Current assets grew 10.7% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-03-04
ADDED
As of February 19, 2026, the registrant had 51,770,857 shares of common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 63 Item 7A.
We generally identify forward-looking statements by using words like anticipate, believe, continue, could, estimate, expect, forecast, future, goal, intend, may, plan, position, possible, potential, predict, project, should, target, will, would, and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements.
All other brands, products, services and feature names or trademarks are the property of their respective owners, including KLOXXADO , which is a registered trademark of Hikma Pharmaceuticals USA Inc.
As of December 31, 2025, the Company has a portfolio of 11 products focused on addressing global public health threats like smallpox, mpox, anthrax, Ebola and opioid overdose emergencies.
As such, the key components of the business structure include the following four product and service categories: Commercial products, consisting of NARCAN Nasal Spray and KLOXXADO , Anthrax Medical Countermeasures ( MCM ) Products, Smallpox - MCM products, and Emergent Bioservices (CDMO) ( Bioservices ).
and Canadian markets, our Commercial business primarily focuses on sales of naloxone products, NARCAN (naloxone HCl) Nasal Spray and KLOXXADO (nalonxone HCI) Nasal Spray.
KLOXXADO Nasal Spray is a prescription pharmaceutical product sold at pharmacies as well as public and government entities through physician-directed or standing order prescriptions.
As a result, the entire $80.0 million of total milestone payments have been received as of December 31, 2025.
Pursuant to the Purchase and Sale Agreement, the Company may receive up to $30.0 million of earn-out payments from Bavarian Nordic based on aggregate net sales of Vaxchora and Vivotif in calendar year 2026.
REMOVED
As of February 25, 2025, the registrant had 54,337,026 shares of common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 60 Item 7A.
We generally identify forward-looking statements by using words like "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal," "intend," "may," "plan," "position," "possible," "potential," "predict," "project," "should," "target," "will," "would," and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements.
All other brands, products, services and feature names or trademarks are the property of their respective owners, including RSDL (Reactive Skin Decontamination Lotion), which was acquired by SERB on July 31, 2024.
As of December 31, 2024, the Company has a product portfolio of 10 products that it is actively developing and/or marketing (vaccines, therapeutics, and drug-device combination products).
As such, the key components of the business structure include the following four product and service categories: NARCAN commercial product, Anthrax - Medical Countermeasures ( MCM ) Products, Smallpox - MCM products and Emergent Bioservices (CDMO) ( Bioservices ).
and Canadian markets, our Commercial business primarily focuses on sales of NARCAN (naloxone HCl) Nasal Spray.
Bavarian Nordic may be required to pay milestone payments related to the development of CHIKV VLP and receipt of marketing approval and authorization in the U.S.
and Europe, and earn-out payments of up to $30.0 million based on aggregate net sales of Vaxchora and Vivotif in calendar year 2026.
Specifically, on July 18, 2024, Bavarian Nordic announced that the European Medicines Agency had validated the marketing authorization application for CHIKV VLP, which triggered a development milestone payment receivable under the Purchase and Sale Agreement to the Company in the amount of $10.0 million (the "First Milestone Payment").
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →